問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳怡仁
下載
2025-11-19 - 2030-06-30
Condition/Disease
Platinum-based therapy-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Test Drug
Navicixizumab
Participate Sites10Sites
Recruiting10Sites
2020-05-01 - 2025-12-31
Participate Sites5Sites
Recruiting5Sites
2024-08-15 - 2026-12-31
Participate Sites9Sites
Not yet recruiting5Sites
Recruiting4Sites
2020-08-01 - 2028-06-30
Participate Sites6Sites
Recruiting6Sites
2022-05-01 - 2025-05-09
Participate Sites7Sites
Recruiting7Sites
2021-12-16 - 2029-12-31
2019-02-01 - 2026-11-30
Participate Sites8Sites
Recruiting8Sites
2019-02-01 - 2026-12-31
2021-05-21 - 2024-06-30
Participate Sites3Sites
Recruiting3Sites
2020-08-31 - 2026-03-31
Terminated1Sites
全部
